ClinicalTrials.gg
RecruitingNCT07919626Updated Nov 5, 2026

Rewiring the Chronic Pain Experience: Single-Session Model of Pain Reprocessing Therapy (PRT) at The Ottawa Hospital

An interventional study of PRT (Pain Reprocessing Therapy) in Chronic Pain, sponsored by Ottawa Hospital Research Institute. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Treatment

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to find out if a one-time session of Pain Reprocessing Therapy (PRT) intervention improves participant's mood and pain. Participants in this 4 hours session will be 40 patients who've been referred to the The Ottawa Hospital Pain Clinic (TOHPC) for chronic pain.

The main questions of this study are:

  • Can we recruit 40 participants within 6 months?
  • Do at least 32 participants complete the session and answer follow up questions?
  • Does 1 session of PRT have a positive impact on participants' mood and pain?

Participants in this study will:

  • Attend 1 session of PRT.
  • Answer questions that relate to their experience of pain and their mood. They will answer these questions immediately before/after the session, 1 week after the session, and 1 month after the session.
  • After the session, some participants will participate in an interview to talk about their experience.
02

Conditions studied

  • Chronic Pain

Browse trials for

03

In context

Chronic Pain

3,227 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum age of 18 years or older at time of consent.
  • Chronic pain persisting for a minimum of 3 months, consistent with the International Association for the Study of Pain (IASP) definition of chronic pain.
  • Self-reported 1-week average pain intensity score between 4/10 and 9/10 on the Brief Pain Inventory (BPI)12 at screening.

    o Note: Individuals scoring less than 4/10 or more than 9/10 will be directed to other pain clinic workshops and available resources (e.g., Power Over Pain)

  • Referred to TOHPC and triaged by a registered nurse, nurse practitioner, or physician to the "diffuse pain" pathway;
  • Completed the initial pain clinic patient education and resource session (PERS) for patients triaged to the "diffuse pain" pathway;
  • Currently waiting for a 1st consultation with the Nurse Practitioner assigned to the "diffuse pain" pathway.
  • Able to read, write, and communicate in English at a level sufficient to engage with research team, the psychoeducational content, and to complete self-report measures.
  • Able to attend a single, in-person 4-hour group session at TOHPC in Ottawa on a scheduled weekday.

Exclusion criteria

Exclusion Criteria:

  • Active mental health symptoms that significantly interfere with the ability to engage with psychoeducational content (e.g., dissociation, active psychosis), or participate in a group setting
  • Cognitive impairment that significantly limits the ability to comprehend study information, provide , or meaningfully engage with psychoeducational content.
  • Scheduled for a major surgical procedure within the study timeframe.
  • Currently receiving other individual or group psychotherapy that directly targets pain, pain cognitions, or pain-related emotional responses within the 12 weeks prior to enrollment.
  • Currently receiving interventional pain management services (e.g., injections, nerve blocks) from another clinic or institution within the 12-week period prior to enrollment through the 3-month follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Pain Reprocessing Therapy (PRT) session

    Behavioral: PRT (Pain Reprocessing Therapy)

Interventions

  • BehavioralPRT (Pain Reprocessing Therapy)

    The intervention involves a single 4-hour PRT in-person group session (up to 20 patients per group) at The Ottawa Hospital Pain Clinic, delivered by a PRT certified clinician. The intervention is a brief mindfulness exercise (mindfulness of breath, energy, emotions, thoughts, sensations), followed by 90 minutes of didactic content focused on pain science education and foundation of pain reprocessing therapy. This includes interactive discussions, self-reflection, and skills building. This is followed by a brief exercise called predictive coding where participants are invited to draw a picture representing their pain. The remainder of the session includes gentle movement, somatic tracking, and practices to increase positive affect induction- specifically leaning into positive or neutral sensations and establishing short-term safety behaviours.

06

What researchers measure

Primary outcomes

  1. Clinical Effectiveness: Brief Pain Inventory (BPI) Pain Intensity and Pain Interference

    Clinical effectiveness outcome measurement tools include Brief Pain Inventory (BPI): Participants will localize their pain through a drop down menu, in which they will select the applicable body part(s) where they experience pain. The BPI Pain Intensity and Pain Interference scales will then be administered. The pain intensity subscale includes 4 pain intensity ratings using an 11-point numerical rating scale (0-10) on current pain, average pain, worst pain during the last 7 days and least pain during the last 24 hours. The pain interference subscale includes 7 interference items that ask the patient to respond using an 11-point numerical rating scale (0-10). These items include the effect on general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life.

    Time frame: Baseline, 1 week post-intervention, 1 month follow up.

  2. Interview

    A random selection of participants will be interviewed regarding their PRT experience.

    Time frame: Interviews will be conducted within 6 months of participating in the PRT session.

  3. Clinical Effectiveness: Pain Self-Efficacy Questionnaire (PSEQ-10)

    Clinical effectiveness outcome measurement tools include Pain Self-Efficacy Questionnaire (PSEQ-10): The PSEQ-10 is a validated 10-item tool for assessing the patient's pain self-efficacy or belief in one's capability to perform activities even when undergoing pain. The 10 items ask the patient to rate their confidence in doing activities on a 7-point numerical rating scale (0-6), with higher scores indicating greater confidence.

    Time frame: Baseline, 1 week post-intervention, 1 month follow up.

  4. Clinical Effectiveness: Patients' Global Impression of Change (PGI-C) Scale

    Clinical effectiveness outcome measurement tools include Patients' Global Impression of Change (PGI-C) Scale: The PGI-C is a validated single- item self-report measure used to assess a patient's perceived change in overall status following a treatment or intervention. Patients select one of 7 options to describe their experience, ranging from "very much worse" to "very much improved." The PGI-C is widely used in chronic pain research and has demonstrated sensitivity to clinically meaningful change across a range of pain populations.

    Time frame: 1 week post-intervention, 1 month follow up.

  5. Clinical Effectiveness: Positive and Negative Affect Scale (PANAS)

    Clinical effectiveness outcome measurement tools include Positive and Negative Affect Scale (PANAS) PANAS is a validated 20-item self-report measure assessing two distinct dimensions of mood: positive affect and negative affect. Participants rate the extent to which they have experienced each emotion using a 5-point Likert scale (1 = very slightly or not at all, 5 = extremely), with higher positive affect scores and lower negative affect scores reflecting better emotional well-being. The PANAS has demonstrated strong reliability and validity across clinical populations, including individuals with chronic pain.

    Time frame: Day of Intervention, 1 week post-intervention, 1 month follow up.

Secondary outcomes

  1. Feasibility of recruitment

    • Rates of participant eligibility and consenting will be tracked o The single session PRT model will be considered feasible if we can recruit our target sample size of 40 participants over a 6-month period.

    Time frame: Baseline

  2. Rate of participant accrual/completion

    • Rates of participant accrual, screening, and 1-week and 1-month assessment completion will be tracked o The evaluation procedures will be considered feasible if we retain more than 80% of participants at 1-month follow-up.

    Time frame: Baseline, Day 7, and Day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2027, 6 months later.

Of 1,295 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 6 months is below that.

Counting every sponsor, half of 1,378 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Nov 5, 2026
StartEst.
Oct 16, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07919626
Responsible party
Sponsor
First posted
Nov 5, 2026
Start date
Oct 16, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Susan Ward, MSW
Contact
SWard@toh.ca
613-737-8899 ext. 72123
Research Co-ordinator
Contact
painresearch@toh.ca
6137378899 ext. 73903
Susan Ward, MSW
principal investigator · The Ottawa Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion